Premium
Improving Cancer Immunotherapy Outcomes Using Biomaterials
Author(s) -
Yan Shuangqian,
Luo Zichao,
Li Zhenglin,
Wang Yu,
Tao Jun,
Gong Changyang,
Liu Xiaogang
Publication year - 2020
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.202002780
Subject(s) - immunoediting , immunotherapy , cancer immunotherapy , medicine , chimeric antigen receptor , cancer , cancer therapy , immune system , immune checkpoint , immunology
Abstract Immunotherapy has made great strides in improving clinical outcomes in cancer treatment. However, few patients exhibit adequate response rates for key outcome measures and desired long‐term responses, and they often suffer systemic side effects due to the dynamic nature of the immune system. This has motivated a search for alternative strategies to improve unsatisfactory immunotherapeutic outcomes. In recent years, biomaterial‐assisted immunotherapy has shown promise in cancer treatment with improved therapeutic efficacy and reduced side effects. These biomaterials have illuminated fundamental mechanisms underlying the immunoediting process, while greatly improving the efficacy of chimeric antigen receptor (CAR) T‐cell therapy, cancer vaccine therapy, and immune checkpoint blockade therapy. This Minireview discusses recent advances in engineered biomaterials that address limitations associated with conventional cancer immunotherapies.